学术探索
学术期刊
新闻热点
数据分析
智能评审

Altering protein turnover in tumor cells: New opportunities for anti-cancer therapies

被引：38
作者：
Demarchi, F
Brancolini, C
机构：
[1] Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, I-33100 Udine, Italy
[2] Lab Nazl Consorzio Interuniv Biotecnol, I-34100 Trieste, Italy
来源：
DRUG RESISTANCE UPDATES | 2005年 / 8卷 / 06期
关键词：
apoptosis; caspases; IAP; IBM; bortezomib; bcl-2; mitochondria; death receptors; apoptosome; hsp; p53; NF-kappa B; noxa; Mcl-1; ubiquitin; proteasome;
D O I：
10.1016/j.drup.2005.12.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The promising effects of the proteasome inhibitor bortezomib (Veleade, PS-341) in the treatment of certain types of cancer have fired up the interest on this multicatalytic proteolytic machinery. A number of recent reviews thoroughly describe various aspects of the ubiquitin-proteasome system and its importance in the control of cell growth and tumorigenesis. Here, we will focus on recent data unveiling a link between the proteasome and some elements of the apoptotic machinery including Bcl-2 members, caspases, IAPs and IAP antagonists. Perturbing their turnover significantly contributes to the apoptotic response and the anti-neoplastic activity of proteasome inhibitors. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码：359 / 368
页数：10
相关论文
共 102 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]   The development of proteasome inhibitors as anticancer drugs [J].
Adams, J .
CANCER CELL, 2004, 5 (05) :417-421
[3]   The proteasome: a novel target for cancer chemotherapy [J].
Almond, JB ;
Cohen, GM .
LEUKEMIA, 2002, 16 (04) :433-443
[4]   Protease inhibitor-induced apoptosis:: accumulation of wt p53, p21WAF1/CIP1 and induction of apoptosis are independent markers of proteasome inhibition [J].
An, WG ;
Hwang, SG ;
Trepel, JB ;
Blagosklonny, MV .
LEUKEMIA, 2000, 14 (07) :1276-1283
[5]   Eukaryotic 20S proteasome catalytic subunit propeptides prevent active site inactivation by N-terminal acetylation and promote particle assembly [J].
Arendt, CS ;
Hochstrasser, M .
EMBO JOURNAL, 1999, 18 (13) :3575-3585
[6]   Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase [J].
Bartke, T ;
Pohl, C ;
Pyrowolakis, G ;
Jentsch, S .
MOLECULAR CELL, 2004, 14 (06) :801-811
[7]   Cancer cell death by programmed necrosis? [J].
Borst, P ;
Rottenberg, S .
DRUG RESISTANCE UPDATES, 2004, 7 (06) :321-324
[8]   Ubiquitin-mediated degradation of the proapoptotic active form of bid - A functional consequence on apoptosis induction [J].
Breitschopf, K ;
Zeiher, AM ;
Dimmeler, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) :21648-21652
[9]   Perspectives for combination therapy to overcome drug-resistant multiple myeloma [J].
Catley, L ;
Tai, YT ;
Chauhan, D ;
Anderson, KC .
DRUG RESISTANCE UPDATES, 2005, 8 (04) :205-218
[10]   A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib [J].
Chauhan, D ;
Catley, L ;
Li, GL ;
Podar, K ;
Hideshima, T ;
Velankar, M ;
Mitsiades, C ;
Mitsiades, N ;
Yasui, H ;
Letai, A ;
Ovaa, H ;
Berkers, C ;
Nicholson, B ;
Chao, TH ;
Neuteboom, STC ;
Richardson, P ;
Palladino, MA ;
Anderson, KC .
CANCER CELL, 2005, 8 (05) :407-419
12345678910